Sauflon Pharmaceuticals Ltd.; Filing of Color Additive Petition, 59560 [E9-27629]
Download as PDF
<![CDATA[
59560
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Notices
Dated: November 12, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–27659 Filed 11–17–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
National Institutes of Health
[Docket No. FDA–2009–C–0543]
Government-Owned Inventions;
Availability for Licensing
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Sauflon Pharmaceuticals Ltd.; Filing of
Color Additive Petition
Administration for Children and
Families
HHS.
AGENCY:
Administration on Children, Youth and
Families; Notice To Award One
Expansion Supplement Grant
AGENCY: Family and Youth Services
Bureau, ACYF, ACF, HHS.
ACTION: Notice to award one expansion
supplement grant.
mstockstill on DSKH9S0YB1PROD with NOTICES
CFDA Number: 93.592.
Legislative Authority: The Family
Violence Prevention and Services Act,
42 U.S.C. 10401 through 10421, as
extended by the Department of Health
and Human Services Appropriations
Act, 2009, Public Law 111–8.
Total Amount of Award: $225,000.
Project Period: September 30, 2009–
September 29, 2010.
SUMMARY: This notice announces the
award of an expansion supplement
grant to one grantee under the Family
and Youth Services Bureau (FYSB)/
Family Violence Prevention and
Services Program. The expansion
supplement award is made to the
Pennsylvania Coalition Against
Domestic Violence, Harrisburg, PA, a
technical assistance provider, to support
their capacity to provide technical
support and training to State and local
domestic violence advocates and social
service agencies. These efforts will
allow FYSB to support collaborative
work to enhance the capacity of
Temporary Assistance to Needy
Families (TANF) and other Federal
programs to provide assistance to
eligible victims of domestic violence.
FOR FURTHER INFORMATION CONTACT:
Marylouise Kelley, Ph.D., Director,
Family Violence Prevention and
Services Program, 1250 Maryland
Avenue, SW., Suite 8216, Washington,
DC 20024. Telephone: 202–104–5756 Email: Marylouise.kelley@acf.hhs.gov.
Dated: November 10, 2009.
Maiso L. Bryant,
Acting Commissioner, Administration on
Children, Youth and Families.
[FR Doc. E9–27667 Filed 11–17–09; 8:45 am]
BILLING CODE 4184–32–P
VerDate Nov<24>2008
16:30 Nov 17, 2009
Jkt 220001
ACTION:
Food and Drug Administration,
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that Sauflon Pharmaceuticals Ltd. has
filed a petition proposing that the color
additive regulations be amended to
provide for the safe use of disodium 1amino-4-[[4-[(2-bromo-1oxoallyl)amino]-2sulfonatophenyl]amino]-9,10-dihydro9,10-dioxoanthracene-2-sulfonate (CAS
Reg. No. 70209–99–3) as a color additive
in contact lenses.
FOR FURTHER INFORMATION CONTACT:
Raphael A. Davy, Center for Food Safety
and Applied Nutrition (HFS–265), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740–
3835, 301–436–1272.
Under the
Federal Food, Drug, and Cosmetic Act
(sec. 721(d)(1) (21 U.S.C. 379e(d)(1))),
notice is given that a color additive
petition (CAP 8C0287) has been filed by
Sauflon Pharmaceuticals Ltd., 49–53
York St., Twickenham, Middlesex, TW1
3LP, United Kingdom. The petition
proposes to amend the color additive
regulations in 21 CFR part 73, subpart
D, Medical Devices to provide for the
safe use of disodium 1-amino-4-[[4-[(2bromo-1-oxoallyl)amino]-2sulfonatophenyl]amino]-9,10-dihydro9,10-dioxoanthracene-2-sulfonate (CAS
Reg. No. 70209–99–3) as a color additive
in contact lenses.
The agency has determined under 21
CFR 25.32(l) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
SUPPLEMENTARY INFORMATION:
Dated: November 10, 2009.
Laura M. Tarantino,
Director, Office of Food Additive Safety,
Center for Food Safety and Applied Nutrition.
[FR Doc. E9–27629 Filed 11–17–09; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A Novel Treatment for Malarial
Infections
Description of Invention: The
inventions described herein are
antimalarial small molecule inhibitors
of the plasmodial surface anion channel
(PSAC), an essential nutrient acquisition
ion channel expressed on human
erythrocytes infected with malaria
parasites. These inhibitors were
discovered by high-throughput
screening of chemical libraries and
analysis of their ability to kill malaria
parasites in culture. Two separate
classes of inhibitors were found to work
synergistically in combination against
PSAC and killed malaria cultures at
markedly lower concentrations than
separately. These inhibitors have high
affinity and specificity for PSAC and
have acceptable cytotoxicity profiles.
Preliminary in vivo testing of these
compounds in a mouse malaria model is
currently ongoing.
Applications: Treatment of malarial
infections.
Advantages: Novel drug treatment for
malarial infections; Synergistic effect of
these compounds on PSAC.
Development Status: In vitro and in
vivo data can be provided upon request.
Market: Treatment of malarial
infection.
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 74, Number 221 (Wednesday, November 18, 2009)]
[Notices]
[Page 59560]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-27629]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-C-0543]
Sauflon Pharmaceuticals Ltd.; Filing of Color Additive Petition
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that
Sauflon Pharmaceuticals Ltd. has filed a petition proposing that the
color additive regulations be amended to provide for the safe use of
disodium 1-amino-4-[[4-[(2-bromo-1-oxoallyl)amino]-2-
sulfonatophenyl]amino]-9,10-dihydro-9,10-dioxoanthracene-2-sulfonate
(CAS Reg. No. 70209-99-3) as a color additive in contact lenses.
FOR FURTHER INFORMATION CONTACT: Raphael A. Davy, Center for Food
Safety and Applied Nutrition (HFS-265), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-1272.
SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic
Act (sec. 721(d)(1) (21 U.S.C. 379e(d)(1))), notice is given that a
color additive petition (CAP 8C0287) has been filed by Sauflon
Pharmaceuticals Ltd., 49-53 York St., Twickenham, Middlesex, TW1 3LP,
United Kingdom. The petition proposes to amend the color additive
regulations in 21 CFR part 73, subpart D, Medical Devices to provide
for the safe use of disodium 1-amino-4-[[4-[(2-bromo-1-oxoallyl)amino]-
2-sulfonatophenyl]amino]-9,10-dihydro-9,10-dioxoanthracene-2-sulfonate
(CAS Reg. No. 70209-99-3) as a color additive in contact lenses.
The agency has determined under 21 CFR 25.32(l) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
Dated: November 10, 2009.
Laura M. Tarantino,
Director, Office of Food Additive Safety, Center for Food Safety and
Applied Nutrition.
[FR Doc. E9-27629 Filed 11-17-09; 8:45 am]
BILLING CODE 4160-01-S
